As PYC is about to release rabbit toxicology results for its lead PPMO asset in Retinitis Pigmentosa type 11, the spotlight has once again fallen on the safety profile of gene therapies.
Applied Genetics Technologies Corporation (AGTC), a Florida-based biotech developing AAV vector-based gene therapies for the treatment of inherited retinal diseases, has reported suspected unexpected serious adverse events in one of its ocular therapy trials.
Four paediatric patients who received a high dose in the company’s Phase 1/2 trial in achromatopsia were reported to have experienced significant inflammation in both segments of the eye approximately one month after dosing.
Nonetheless, AGTC has made the decision to continue clinical development of the therapy, one of five it has under development for inherited retinal diseases. Its lead pipeline product is a therapy for X-linked Retinitis Pigmentosa (XLRP). Of the 29 patients in its completed Phase 1/2 XLRP trial, 4 patients suffered retinal detachment from the gene therapy’s subretinal delivery procedure.
The company also has two neurodegenerative candidate therapies and one in otology. Its current market cap is US$138m, a third of the value of its 52 week high.
https://www.fiercebiotech.com/biotech/kids-suffer-serious-adverse-reactions-agtc-gene-therapy-trial
https://ir.agtc.com/events-and-presentations
- Forums
- ASX - By Stock
- PYC
- Ann: Annual Report to shareholders
Ann: Annual Report to shareholders, page-13
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
17.0¢ |
Change
-0.015(8.11%) |
Mkt cap ! $793.2M |
Open | High | Low | Value | Volume |
18.0¢ | 18.0¢ | 17.0¢ | $419.2K | 2.405M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 326555 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 222720 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 319167 | 0.170 |
5 | 252135 | 0.165 |
9 | 322378 | 0.160 |
8 | 205685 | 0.155 |
11 | 356186 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.175 | 220600 | 3 |
0.180 | 682072 | 5 |
0.185 | 1295297 | 10 |
0.190 | 546611 | 9 |
0.195 | 636637 | 7 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
PYC (ASX) Chart |